Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer.

ABSTRACT:

Importance

Although bevacizumab has been used in the treatment of ovarian cancer, its optimal use is unknown.

Objective

To investigate time-dependent changes in the outcomes of bevacizumab therapy.

Design, setting, and participants

This cohort study was conducted using published data from 7 previous randomized phase 3 clinical trials with bevacizumab (ICON7, GOG-0218, BOOST, GOG-0213, OCEANS, AURERIA, and MITO16B) from January 10 to January 31, 2023. From 2 ancillary analyses of the ICON7 trial with individual patient data and tumor gene expression profiles, an ICON7-A cohort was generated comprising 745 cases. From other studies, published Kaplan-Meier curves were graphically analyzed.

Exposures

Bevacizumab treatment vs placebo or no treatment.

Main outcome

SUBMITTER: Takamatsu S 

PROVIDER: S-EPMC10398412 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature